-
EP3706776
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3706776
| EP3706776 - IMMUNOGENIC COMPOSITIONS AND USES THEREFOR [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 30.06.2023 Database last updated on 03.09.2024 | |
| Former | Request for examination was made Status updated on 14.08.2020 | ||
| Former | The international publication has been made Status updated on 18.05.2019 | Most recent event Tooltip | 23.07.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Epiaxis Therapeutics Pty Ltd Level 6, Bancroft Building QIMR Berghofer Medical Research Institute 300 Herston Road Herston QLD 4006 / AU | [2020/38] | Inventor(s) | 01 /
RAO, Sudha 102 Buxton Street Deakin Australian Capital Territory 2600 / AU | [2020/38] | Representative(s) | Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB | [2020/38] | Application number, filing date | 18875545.8 | 08.11.2018 | [2020/38] | WO2018AU51204 | Priority number, date | AU20170904540 | 08.11.2017 Original published format: AU 2017904540 | [2020/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019090390 | Date: | 16.05.2019 | Language: | EN | [2019/20] | Type: | A1 Application with search report | No.: | EP3706776 | Date: | 16.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.05.2019 takes the place of the publication of the European patent application. | [2020/38] | Search report(s) | International search report - published on: | AU | 16.05.2019 | (Supplementary) European search report - dispatched on: | EP | 12.07.2021 | Classification | IPC: | A61K38/17, A61K39/395, A61P37/00, A61P35/00, A61P31/00, A61K35/17, A61K38/10, A61K39/00, A61K45/06 | [2021/32] | CPC: |
A61K35/17 (EP,AU,US);
A61K38/005 (AU,US);
A61K38/10 (EP,US);
A61K39/395 (EP);
A61K39/39566 (AU);
A61K45/06 (EP,US);
A61K47/68 (AU,US);
A61P31/00 (EP,AU,US);
A61P35/00 (EP,AU);
A61P35/04 (US);
A61P37/00 (EP,AU);
A61P37/02 (US);
C07K16/2818 (EP,US);
G01N33/505 (AU,US);
G01N33/566 (AU,US);
G01N33/56972 (EP,AU,US);
G01N33/574 (AU);
G01N33/5743 (AU,US);
G01N33/57484 (EP,US);
A61K2039/505 (EP);
A61K2121/00 (AU);
C07K14/4702 (AU);
C07K16/18 (AU);
C07K16/40 (AU);
G01N2333/47 (AU);
G01N2333/4704 (EP,US);
G01N2333/912 (EP,US);
| C-Set: |
A61K39/395, A61K2300/00 (EP)
|
| Former IPC [2020/38] | A61K38/17, A61K39/395, A61P37/00, A61P35/00, A61P31/00, A61K35/17 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/38] | Title | German: | IMMUNOGENE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON | [2020/38] | English: | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | [2020/38] | French: | COMPOSITIONS IMMUNOGENIQUES ET LEURS UTILISATIONS | [2020/38] | Entry into regional phase | 04.06.2020 | National basic fee paid | 04.06.2020 | Search fee paid | 04.06.2020 | Designation fee(s) paid | 04.06.2020 | Examination fee paid | Examination procedure | 06.09.2019 | Request for preliminary examination filed International Preliminary Examining Authority: AU | 04.06.2020 | Examination requested [2020/38] | 08.02.2022 | Amendment by applicant (claims and/or description) | 29.06.2023 | Despatch of a communication from the examining division (Time limit: M06) | 08.01.2024 | Reply to a communication from the examining division | 22.07.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 13.11.2020 | Renewal fee patent year 03 | 19.10.2021 | Renewal fee patent year 04 | 15.09.2022 | Renewal fee patent year 05 | 26.02.2024 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 30.11.2023 | 06 M06 Fee paid on 26.02.2024 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO02079499 (WYETH CORP [US], et al); | [XYA]WO2004043386 (TOLERRX INC [US], et al); | [XY]WO2008051826 (ORGANON NV [NL], et al); | [XY]WO2011094273 (VERTEX PHARMA [US], et al); | [XY]WO2014022759 (DANA FARBER CANCER INST INC [US], et al); | [XY]WO2014066834 (UNIV CHICAGO [US]); | [XYA]WO2015039187 (UNIV CANBERRA [AU]); | [XY]WO2015112800 (REGENERON PHARMA [US]); | [XYA]WO2016029262 (UNIV CANBERRA [AU]); | [XY]WO2016100882 (NOVARTIS AG [CH], et al); | [XY]WO2017132728 (UNIV CANBERRA [AU]); | by applicant | US5783405 | US2002120129 | US2002142980 | US2002150936 | US2003073640 | US2004009922 | US2004192626 | US2005020525 | US2005059817 | US2005176018 | US2005234232 | US2005239731 | US2005282188 | US2009047272 | US2013136742 | US2015266935 |